Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway
Authors:
Open Access
- 14 March 2012
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 39 (7) , 7743-7753
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a progressive chronic kidney disease. To date there are no effective medicines to halt development and growth of cysts. In the present study, we explored novel effects of celecoxib (CXB), a COX-2 specific inhibitor, on primary cultures of human ADPKD cyst-lining epithelial cells. Primary cultures of ADPKD cyst-lining epithelial cells were obtained from five patients. Effects of CXB were measured by various assays to detect BrdU incorporation, apoptosis and proliferation in vitro. Additionally, effects of CXB on kidney weight, the cyst index, the fibrosis index, blood urea nitrogen (BUN), serum creatinine (SCr), serum 6-keto-PGF-1α, serum thromboxane-2 (TXB2) and renal PCNA expression were assessed in Han:SPRD rat, a well-characterized rodent model of PKD. CXB inhibited proliferation of ADPKD cyst-lining epithelial cells, blocked the release of VEGF from the cells and induced extensive apoptosis in a time- and dose-dependent manner. Moreover, CXB up-regulated the cell cycle negative regulator p21CIP/WAF1 and the cell cycle positive regulator Cyclin A, blocked ERK1/2 phosphorylation, induced apoptotic factors (Bax and caspase-3) and reduced Bcl-2. Furthermore, CXB inhibited the expression of VEGFR-2 and Raf-1 in ADPKD cyst-lining epithelial cells. CXB markedly reduced the cyst index, the fibrosis index, leukocyte infiltration, BUN, SCr, serum 6-keto-PGF-1α, TXB2 and renal PCNA expression in Han:SPRD rat. We demonstrated for the first time that CXB could suppress renal cyst-lining growth both in vitro and in vivo in Han:SPRD rat. CXB can inhibit proliferation, suppress cell cycle progression, and induce apoptosis in ADPKD cyst-lining epithelial cells through the inhibition of the VEGF/VEGFR-2/Raf-1/MAPK/ERK signaling pathway.Keywords
This publication has 43 references indexed in Scilit:
- Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell linesAnti-Cancer Drugs, 2010
- Endothelial progenitor cell transplantation improves long‐term stroke outcome in miceAnnals of Neurology, 2010
- Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosisAnnals of Neurology, 2010
- Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their EfficacyKidney and Blood Pressure Research, 2009
- Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific BiomarkersJournal of Clinical Oncology, 2009
- Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO studyBreast Cancer Research and Treatment, 2008
- Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotideCardiovascular Research, 2008
- Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD)Kidney International, 2005
- Alterations in renal cytosolic phospholipase A 2 and cyclooxygenases in polycystic kidney diseaseThe FASEB Journal, 2002
- Mutations of the BRAF gene in human cancerNature, 2002